logo-loader
Acasti Pharma Inc

Acasti Pharma says independent study highlights effectiveness of CaPre in treating hypertriglyceridemia

The study found that CaPre, which treats severe hypertriglyceridemia, was well-tolerated in healthy subjects as multiple oral doses

Acasti Pharma Inc -
Acasti is on track to report topline results from its TRILOGY studies on CaPre in the next couple of months

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) announced Thursday that a leading medical journal has published results from a new study of its lead drug candidate CaPre. 

The study, entitled “Evaluation of OM3-PL/FFA Pharmacokinetics After Single and Multiple Oral Doses in Healthy Volunteers,” was published in Clinical Therapeutics. 

It found that CaPre, which treats severe hypertriglyceridemia, was well-tolerated in healthy subjects as multiple oral doses of one, two and four grams a day.

READ: Acasti Pharma on pace to release Phase 3 trial results of lead drug candidate CaPre in December

The study looked at 42 randomized healthy volunteers who received a single dose of CaPre for 14 days. On day 15, the subjects received a high-fat breakfast, which can contribute to hypertriglyceridemia (HTG), or elevated levels fat molecules in the bloodstream.

Other findings indicated that CaPre’s pharmacokinetic parameters appeared to be nearly dose-proportional over the 1 to 4 grams per day dose range.

Researchers also found that the bioavailability of CaPre did not appear to be affected by the fat content of the breakfast that was consumed by subjects on day 15.

The study’s co-author Dr Robert Hegele said that there is a need for a formulation with high bioavailability, regardless of fat intake, since a low-fat diet is part of the management of patients with HTG.

“The study results for CaPre demonstrated greater exposure at higher doses, irrespective of fat content of the meal,” Hegele said.

Acasti’s CEO Pierre Lemieux said that the study further enforced the favourable dose response reported in the company’s clinical trials. “This is important due to the fact patients randomized to CaPre in the TRILOGY trials all received 4 grams per day, compared to our Phase 2 studies that included a range of doses from 1 gram, 2 gram and 4 grams per day.”

Lemieux also told shareholders that exposure was unaffected by fat content of the meal, an “important distinction” as currently available prescription omega-3s are bound to ethyl-esters, which require patients to take their omega-3s with a high-fat meal for ideal absorption.

Laval, Quebec-based Acasti is on track to report topline results from its TRILOGY studies on CaPre in the next couple of months.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Acasti Pharma Inc

Price: 2.8 CAD

Market: TSX-V
Market Cap: $238.91 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Acasti Pharma signs long term deal with Aker Bio Marine to...

Acasti Pharma  (CVE: ACST) Chief Operations and Scientific Officer Pierre Lemieux joined Steve Darling to discuss the company signing a long term deal to a have a consistent supply of the Krill Oil which is critical in the development of their flagship product CaPre. Lemieux discussing...

2 weeks, 3 days ago

2 min read